OBJECTIVE: In cancer patients, the balance between neutrophil (N) and lymphocyte (L) cell counts fluctuates with advancing disease. The objective of our study was to determine the prognostic implications of the N/L ratio in the peripheral blood of gastric cancer patients. METHODS: Study participants were identified from a prospective cohort of patients with advanced gastric cancer in Japan (n = 1,220). RESULTS: The median baseline N/L was 2.58 (range, 0.63-12.7). Univariate analysis revealed that patients with an N/L > pr =2.5 (n = 644) had a significantly poorer prognosis than those with an N/L <2.5 (n = 576; log rank test, p = 0.019 x 10(-12)). The median survival times for these two groups were 239 (95% confidence interval, CI, 217-251 days) and 363 days (95% CI, 334-406 days), respectively, while the 1-year survival rates were 30 (95% CI, 26-34%) and 50% (95% CI, 45-54%), respectively. A multivariate Cox model established a significant relationship between the N/L ratio and survival (adjusted hazard ratio = 1.52; 95% CI, 1.32-1.75; p = 0.077 x 10(-8)). CONCLUSIONS: These results suggest that the N/L ratio is an independent prognostic factor in advanced gastric cancer. Measurement of this ratio may serve as a clinically accessible and useful biomarker for patient survival. (c) 2008 S. Karger AG, Basel
OBJECTIVE: In cancerpatients, the balance between neutrophil (N) and lymphocyte (L) cell counts fluctuates with advancing disease. The objective of our study was to determine the prognostic implications of the N/L ratio in the peripheral blood of gastric cancerpatients. METHODS: Study participants were identified from a prospective cohort of patients with advanced gastric cancer in Japan (n = 1,220). RESULTS: The median baseline N/L was 2.58 (range, 0.63-12.7). Univariate analysis revealed that patients with an N/L > pr =2.5 (n = 644) had a significantly poorer prognosis than those with an N/L <2.5 (n = 576; log rank test, p = 0.019 x 10(-12)). The median survival times for these two groups were 239 (95% confidence interval, CI, 217-251 days) and 363 days (95% CI, 334-406 days), respectively, while the 1-year survival rates were 30 (95% CI, 26-34%) and 50% (95% CI, 45-54%), respectively. A multivariate Cox model established a significant relationship between the N/L ratio and survival (adjusted hazard ratio = 1.52; 95% CI, 1.32-1.75; p = 0.077 x 10(-8)). CONCLUSIONS: These results suggest that the N/L ratio is an independent prognostic factor in advanced gastric cancer. Measurement of this ratio may serve as a clinically accessible and useful biomarker for patient survival. (c) 2008 S. Karger AG, Basel
Authors: Youngjoo Lee; Sun Hye Kim; Ji-Youn Han; Heung Tae Kim; Tak Yun; Jin Soo Lee Journal: J Cancer Res Clin Oncol Date: 2012-07-07 Impact factor: 4.553
Authors: Ahmet Taner Sümbül; Ahmet Sezer; Hüseyin Abalı; Fatih Köse; Ilhami Gültepe; Hüseyin Mertsoylu; Sadık Muallaoğlu; Özgür Özyılkan Journal: Int Urol Nephrol Date: 2014-02-13 Impact factor: 2.370
Authors: Jenny G Turcott; María Del Rocío Guillen Núñez; Diana Flores-Estrada; Luis F Oñate-Ocaña; Zyanya Lucia Zatarain-Barrón; Feliciano Barrón; Oscar Arrieta Journal: Support Care Cancer Date: 2018-03-17 Impact factor: 3.603
Authors: Sam C Wang; Joanne F Chou; Vivian E Strong; Murray F Brennan; Marinela Capanu; Daniel G Coit Journal: Ann Surg Date: 2016-02 Impact factor: 12.969